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The involvement of the gut microbiota in metabolic disorders, and the ability of whole grains to 
affect both host metabolism and gut microbial ecology, suggest that some benefits of whole 
grains are mediated through their effects on the gut microbiome. Nutritional studies that assess 
the effect of whole grains on both the gut microbiome and human physiology are needed. We 
conducted a randomized cross-over trial with four-week treatments in which 28 healthy humans 
consumed a daily dose of 60 g of whole-grain barley (WGB), brown rice (BR), or an equal 
mixture of the two (BR+WGB), and characterized their impact on fecal microbial ecology and 
blood markers of inflammation, glucose and lipid metabolism. All treatments increased 
microbial diversity, the Firmicutes/Bacteroidetes ratio, and the abundance of the genus Blautia in 
fecal samples. The inclusion of WGB enriched the genera Roseburia, Bifidobacterium and 
Dialister, and the species Eubacterium rectale, Roseburia faecis and Roseburia intestinalis. 
Whole grains, and especially the BR+WGB treatment, reduced plasma interleukin-6 (IL-6) and 
peak postprandial glucose. Shifts in the abundance of Eubacterium rectale were associated with 
changes in the glucose and insulin postprandial response. Interestingly, subjects with greater 
improvements in IL-6 levels harbored significantly higher proportions of Dialister and lower 
abundance of Coriobacteriaceae. In conclusion, this study revealed that a short-term intake of 
whole grains induced compositional alterations of the gut microbiota that coincided with 
improvements in host physiological measures related to metabolic dysfunctions in humans. 
Keywords: inflammation, gut microbiota, metabolic disorders, whole grains 
 
Introduction 
Obesity is associated with an increased risk in cardiovascular disease, type-2 diabetes, non-
alcoholic fatty-liver disease and some cancers, and constitutes a major health concern worldwide 
(Cornier et al., 2008; Hu, 2011). A diet high in whole grains and dietary fibers has been shown to 
improve metabolic parameters related to these metabolic disorders (Liu et al., 1999; Fung et al., 
2002; Liu et al., 2003; Murtaugh et al., 2003; Jensen et al., 2004; Nettleton et al., 2008). The 
mechanisms responsible for the benefits of whole grains are not completely understood. It has 
been proposed that the dietary fiber present in whole grains increases the viscosity of the digesta 
and binds to bile acids in the small intestine, thus contributing to decreased sugar and lipid 
(cholesterol) absorption (Behall et al., 2004; Alminger and Eklund-Jonsson, 2008). In addition, 
phytochemicals and other bioactive compounds in whole grains might provide metabolic benefits 
(Adom and Liu, 2002; Nilsson et al., 2006; Harris and Kris-Etherton, 2010). Furthermore, the 
metabolic inflammation associated with obesity and related diseases is now considered to trigger 
metabolic dysfunctions (Gregor and Hotamisligil, 2011), and the benefits of whole grains might 
be due to an anti-inflammatory action (Nilsson et al., 2008b; Rosén et al., 2011). In this respect, 
bacterial fermentation of undigestible constituents of whole grains in the gastrointestinal tract has 
been suggested to be partly responsible for the benefits of whole grains (Nilsson et al., 2008a; 
North et al., 2009; Harris and Kris-Etherton, 2010). 
A consideration of the gut microbiome in the context of the health effects of whole grains has 
become especially relevant in light of recent research that indicated an etiological role of gut 
bacteria in metabolic disorders. Obesity and type 2 diabetes have been linked to alterations in the 
intestinal microbiota in both the humans and animal models (Ley et al., 2006; Turnbaugh et al., 
2006; Cani et al., 2007; Larsen et al., 2010; Vijay-Kumar et al., 2010). If these aberrations 
contribute to human disease is still unclear, but pathophysiological indicators are reduced in 
animal models when animals are kept germ-free or when treated with antibiotics, and 
manifestations of disease can be transmitted through the gut microbiota (Ley et al., 2005; Cani et 
al., 2008; Vijay-Kumar et al., 2010; Henao-Mejia et al., 2012). Proposed mechanisms by which 
microbiota contribute to metabolic aberrations are the induction of lipolysis leading to increased 
fat storage (Bäckhed et al., 2007), hepatic de-novo synthesis of triglycerides (Bäckhed et al., 
2004) and the alteration of bile acid metabolites with consequences to lipid metabolism in the 
host (Claus et al., 2011). Furthermore, the gut microbiome might exacerbate the systemic 
inflammation associated with obesity and related metabolic disorders (Hotamisligil, 2006; Ding 
et al., 2010), possibly through the induction of endotoxemia driven by lipopolysaccharide 
translocation through the intestinal epithelium (Cani et al., 2007; Amar et al., 2008; Cani et al., 
2008; Li and Hotamisligil, 2010). 
The interplay between the gut microbiota and host metabolism and the ability of whole grains to 
affect both of these aspects suggest that one mechanism by which whole grains confer their 
benefits might be through a modulation of the gut microbiome. Recent research has revealed that 
the composition and metabolism of the gut microbiota can be modulated through prebiotics and 
fiber (Flint et al., 2007; Louis et al., 2007), and these carbohydrates have been shown to improve 
metabolic markers in experimental models (Cani et al., 2007; Neyrinck et al., 2011). Despite 
these encouraging findings, human studies that investigate the effects of whole grains and cereal 
fibers on host metabolism have neglected, until now, to characterize the gut microbiome and 
explore its potential contribution to health improvements (Tilg and Kaser, 2011). In addition, 
although the effect of fiber on the gut microbiota has been recently studied in experimental 
animals (Neyrinck et al., 2011; Van den Abbeele et al., 2011), information on how whole grains 
impact human gut microbiome composition is lacking. 
The aims of this study were to characterize the impact of the incorporation of whole grains to an 
otherwise unrestricted diet on gut microbial ecology in healthy human subjects, and to 
investigate whether a connection with metabolic and immunological improvements exists. For 
this purpose, we performed a human crossover study with three four-week whole grain 
treatments, and collected fecal and blood samples at baseline and at the end of each treatment. 
The effect of whole grains on fecal microbiota composition was characterized by pyrosequencing 
of 16S rRNA gene tags, and inflammatory and metabolic markers related to metabolic 
dysfunctions in humans were measured in blood samples. The molecular characterization of 
fecal microbiota in parallel to host phenotyping allowed an investigation of associations between 
diet-induced metabolic changes and shifts in the gut microbiome. 
 
Materials and methods 
Subjects 
The human trial was approved by the Institutional Review Board of the Kansas State University 
(IRB Approval Number: 5298), and written informed consent was obtained from all subjects. 
Healthy participants (see Supplementary materials for inclusion/exclusion criteria) were 
recruited through leaflets distributed on-campus by the College of Human Nutrition at the 
Kansas State University, Manhattan, KS. Twenty-eight participants, 17 females and 11 males 
(age 25.9±5.5 years), took part in the study. 
Test meals 
Whole grain Prowashonupana Barley (Sustagrain Barley Quick Flakes, ConAgra Mills, Omaha, 
NE, USA) and whole-grain brown rice (Insta Grains Brown Rice Flakes, Briess, Chilton, WI, 
USA) flakes were used in this study. Three test meals with different amounts of total dietary 
fiber were included: a barley treatment (WGB), consisting of 60 g of barley (18.7 g total dietary 
fiber); a brown rice and barley treatment (BR+WGB), consisting of 30 g each barley and BR 
(11.5 g total dietary fiber); and a BR treatment, consisting of 60 g of BR (4.4 g total dietary 
fiber). Subjects were provided with individual bags containing a daily dose of the corresponding 
treatment (60 g of flakes). Nutritional information of the whole-grain flakes used in the study is 
available in the Supplementary materials and Supplementary Table S1. 
Study design 
The study was conducted as a randomized crossover trial over 17 weeks (Figure 1). The first 
week served as a baseline period, after which each subject underwent three four-week dietary 
treatments (BR, BR+WGB, WGB) in random order, and interspaced by two-week washout 
periods. The study was conducted under free-living conditions, and no dietary restrictions were 
imposed except that subjects were expected to be non-vegetarian. Subjects were instructed to 
consume the 60 g of flakes daily either plain, with yogurt or with milk, without time restrictions. 
Weekly symptom diaries were completed by the subjects in which they self-reported bowel 
movement, discomfort, flatulence, bloating, stool consistency and general well-being on a scale 




Figure 1 Experimental design. Time line of the randomized crossover trial. Three four-week 
dietary treatments were assessed in succession. The treatments were interspaced by two-week 
washout (WO) periods. Blood and stool samples (indicated by arrows) were collected during the 
baseline (BL) and at the end of each treatment period. 
 
Subject parameters and determination of metabolic and immunological markers 
Subject parameters were measured at the Human Metabolism Laboratory at Kansas State 
University. Total body composition was assessed at baseline with dual-energy X-ray 
absorptiometry (Prodigy GE-Lunar, GE, Waukesha, WI, USA). Blood samples were drawn at 
baseline and at the end of each dietary treatment after a 12 h overnight fast. An initial blood 
sample was drawn (time 0). A standard drink containing 75 g of glucose (Fisher Scientific, 
Pittsburg, PA, USA) was consumed within 10 min, and blood samples were collected at 15, 30, 
45, 60, 90 and 120 min for the determination of postprandial glucose and insulin responses. 
Blood was immediately placed in tubes containing K2-EDTA (Vacutainer, BD, Franklin Lakes, 
NJ, USA) and centrifuged at 1000–1500x g for 13 min at 5–10 °C. Aliquots of plasma were 
transferred into tubes for storage at −80 °C until further testing. 
Glucose and insulin were measured in plasma samples in duplicate using an automated analyzer 
(YSI 2300, YSI Life Sciences, Yellow Springs, OH, USA) and the Human Gut Hormone 
Immunoassay kit (Milliplex, EMD Millipore, Billerica, MA, USA) with a dual laser flow 
cytometer (Luminex, EMD Millipore, Billerica, MA, USA), respectively. A lipid profile, 
consisting of total cholesterol, high-density lipoprotein (HDL) and non-HDL cholesterol was 
performed on the preprandial samples (time 0) using the Cholestech LDX System (Alere, 
Waltham, MA, USA). Three markers of inflammation were measured in plasma samples by 
enzyme-linked immunosorbent assays (in duplicate): lipopolysaccharide-binding protein (LBP) 
(USCN Life Science and Technology, Huston, TX, USA), high-sensitive C-reactive protein (hs-
CRP) (Symansis, Timaru, New Zealand), and interleukin 6 (IL-6) (R&D Systems, Minneapolis, 
MN, USA). 
Short-chain fatty acids were quantified in fecal samples by gas chromatography as described in 
the Supplementary materials. 
Compositional analysis of the fecal microbiota by pyrosequencing 
Despite the fact that fecal samples represent microbial communities that are shed from the gut 
and not resident, they provide a good overview over the microbiota present in the distal colon, 
and are the most practical samples that can be obtained from subjects participating in nutritional 
trials. Subjects provided fecal samples within 24 h of blood sampling and 2 h of defecation. Fecal 
material and 1:10 fecal homogenates in phosphate-buffered saline (pH=7) were immediately 
frozen (−80 °C) and stored until further processing. Bacterial DNA was extracted from fecal 
homogenates as described by Martínez et al. (2010), using the QIAamp DNA Stool Mini Kit 
(Qiagen, Valencia, CA, USA) in combination with enzymatic and mechanical cell lysis. 
Pyrosequencing of amplicons obtained by PCR with universal primers targeting the V1–V3 
region of the 16 S rRNA gene was performed as previously described (Martínez et al., 2010), 
using the 454 Genome Sequencer FLX with GS FLX Titanium series reagents at the Core for 
Applied Genomics and Ecology (University of Nebraska). Sequences obtained during this study 
are deposited in the MG-RAST server under the accession numbers 4498555.3, 4498556.3 and 
4498557.3. 
Sequence processing was performed combining features of QIIME (Caporaso et al., 2010) and 
the Ribosomal Database Project pipeline (Cole et al., 2009). Three-thousand quality-controlled 
sequences per sample were randomly selected and used for taxonomic classification. Sequences 
were assigned to a bacterial phylum, family and genus using the Classifier tool of the Ribosomal 
Database Project (Wang et al., 2007). In addition, sequences were assigned to operational 
taxonomic units with 97% sequence homology as described in the Supplementary materials. 
Chao1 species richness estimator, and Shannon's and Simpson's (defined as 1-Dominance) 
diversity indices were computed with QIIME. 
Query for genes encoding β-glucanases in genomes of human gut microbes 
Bacterial genomes available in the Joint Genome Institute database were used to identify large-
bowel associated bacteria with β-glucanase encoding activity. The integrated microbial genomes 
platform of Joint Genome Institute was used to conduct this survey. A list of the strains included 
in the survey is presented in the Supplementary materials. For the species identified to contain β-
glucanase genes, their abundance in the fecal microbiota of our subjects was quantified by 
BLASTn. 
Statistics 
Results are presented as means±s.d. Differences in bacterial taxa and host phenotypes among 
treatments were determined by one-way analysis of variance with repeated measures in 
combination with Tukey's post-hoc tests, and P<0.05 was considered statistically significant. If 
the data were not normally distributed, values were subjected to transformations such as square 
root or logarithm with base 10 to achieve normality. If normality could not be achieved through 
transformations, the non-parametric Kruskal-Wallis test was performed. When only two groups 
of data were compared, Student's t-tests were performed. Correlations between host parameters 
and bacterial populations were assessed by Pearson's correlation tests using GraphPad Prism 
version 5.00 (GraphPad Software, La Joya, CA, USA). Associations between inflammatory 
markers and gut microbiome composition were also analyzed through linear models using SAS 
(SAS Institute Inc., Cary, NC, USA). Additional information on the statistical methods can be 
found in the Supplementary materials. 
 
Results 
Physiologic, metabolic and microbiome characteristics of the study population 
Twenty-eight volunteers, 11 males and 17 females, participated in the nutritional trial, and 
subjects' parameters are presented in Table 1. Based on percent body fat, 13 subjects were 
classified as overweight, using as cutoff values >31% body fat for women and >25% for men. 
This Metabolic and immunological markers included in the study were plasma fasting glucose 
and insulin levels, glycemic and insulin postprandial response, a lipid panel (total cholesterol, 
HDL, non-HDL), and inflammatory markers (hs-CRP, IL-6 and LBP). The rationale for the 
inclusion of these markers is their suitability in determining the progression of metabolic 
aberrancies and the risk of cardiovascular disease (Schumann et al., 1990; Spranger et al., 2003; 
Cardellini et al., 2005; Ridker, 2009), and their association with obesity (Sun et al., 2010). 
Accordingly, positive correlations between body fat and all three inflammatory markers were 
observed (Figures 2a–c). LBP and hs-CRP were highly correlated (r=0.90, P<0.0001) (Figure 
2d). The linear model identified body fat as a significant factor affecting IL-6 (P<0.01), hs-CRP 
(P<0.0001) and LBP (P<0.0001). Furthermore, significant positive correlations existed between 
IL-6 and postprandial glucose response (Figure 2a). Together, these associations substantiate the 






Associations among host physiological characteristics and their correlation with bacterial 
populations in fecal samples at baseline. Heatmap displaying correlation coefficients between 
metabolic and physiological parameters of the study population at baseline (a). Correlations 
between hs-CRP with body fat (b), LBP with body fat (c), hs-CRP and LBP (d), hs-CRP and 
Ruminococcaceae (e), LBP with Ruminococcaceae (f) and Oscillibacter with postprandial AUC 
glucose (g). Pearson's correlation (r) and the corresponding P-values are presented. 
  
Table 1. Baseline characteristics of the 28 subjects, and differentiated by gender and 
percent body fat (values are presented as mean±s.d.) 


















Age 25.9±5.4 26.7±5.4 25.4±5.8 NS 28.6±6.6 23.6±3.0 < 
0.05 
Weight (kg) 72.3±18.3 87.7±17.1 62.3±10.5 < 
0.001 




25.1±4.5 27.4±4.8 23.6±3.7 < 
0.05 




20.8±10.3 20.2±11.6 21.2±9.8 NS 29.7±8.1 13.1±3.6 < 
0.001 
Body fat (%) 29.6±11.0 22.8±8.5 34.0±10.8 < 
0.01 




              
 Total 
cholesterol 
4.86±1.12 4.07±0.69 5.22±1.67 < 
0.01 








1.65±0.42 1.30±0.28 1.84±0.57 < 
0.001 










43.44±18.86 42.76±20.55 44.93±21.14 NS 49.77±19.92 40.34±18.38 NS 
Inflammatory 
markers 























































Abbreviations: hs-CRP, high-sensitive C-reactive protein; IL, interleukin; LBP, 
lipopolysaccharide-binding protein; NS, not significant. 
aWomen with over 31% body fat, and men with over 25% body fat were considered as 
overweight individuals. All others were considered lean. 
 
Pyrosequencing revealed that the baseline fecal microbiota of the participants was dominated by 
the phyla Firmicutes and Bacteroidetes, with lower proportions of Verrucomicrobia and 
Actinobacteria, in agreement with previous molecular characterizations of the human fecal 
microbiota (Ley et al., 2006; Martínez et al., 2010). We investigated whether associations 
between host phenotypes and microbial populations existed (Supplementary Figure S1). No 
significant correlation was observed between any bacterial group and body fat or BMI, although 
overweight subjects harbored significantly lower abundances of Ruminococcaceae (10.8±5.4% 
versus 17.9±9.9%, P<0.05) and Faecalibacterium (1.8±1.8% versus 3.7±2.5%, P<0.05). The 
analysis revealed negative correlations between the family Ruminococcaceae and all the three 
inflammatory markers at baseline (Figures 2e and f, and Supplementary Figure S1). Within this 
family, the genera Faecalibacterium and Ruminococcus displayed negative correlations with hs-
CRP (r=−0.48, P<0.05, and r=−0.60, P<0.01, respectively). The analysis also revealed a 
negative association between Oscillibacter and postprandial glucose area under the curve (Figure 
2f). Regarding the markers of lipid metabolism, proportions of Bacteroidetes, Bacteroidaceae 
and Bacteroides were positively correlated to plasma HDL values (r=0.54, P<0.05; r=0.56, 
P<0.05; r=0.56, P<0.05; respectively) (Supplementary Figure S2). 
Effects of whole grains on fecal microbial communities 
Sequence data obtained by pyrosequencing were used to establish the effects of whole grains on 
the gut microbiota composition. This analysis revealed that whole grains had a measurable effect 
on gut microbiota composition. All three treatments significantly increased the bacterial diversity 
measured by Shannon's and Simpson's indices but not by Chao1 (Supplementary Figure S3). 
These results indicated an increase in community evenness (Shannon's and Simpson's), but not in 
total species richness (Chao1). 
In accordance to previous studies that assessed the effect of diet on the gut microbiome 
(Martínez et al., 2010; Davis et al., 2011), substantial inter-individual variation was observed in 
response to whole grains (Supplementary Table 2). Despite this variability, several diet-induced 
shifts reached statistical significance in the entire study population. The proportion of the phylum 
Firmicutes increased, while Bacteroidetes were reduced (Table 2). The decrease in Bacteroidetes 
was largely caused by a reduction of the genus Bacteroides (Table 2). 
Table 2 
Abundance of dominant bacterial taxa (% of total microbiota) in fecal samples as 
determined by 454 pyrosequencing (values are presented as mean±s.d.) 
  Baseline BR BR+WGB WGB P-
value 
Confirmatio
n by linear 
model 
Phylum 
  Baseline BR BR+WGB WGB P-
value 
Confirmatio




















 Verrucomicrobia 1.82±1.98 1.34±1.53 0.68±0.80 0.59±0.80 NS Yes 
 Actinobacteria 1.24±0.97 1.42±1.78 2.23±3.32 2.05±2.73 NS Yes 











 Lachnospiraceae 22.21±7.90 22.62±7.91 23.11±6.56 22.65±7.63 NS Yes 
 Ruminococcaceae 14.64±8.76 17.32±8.90 16.53±8.06 15.82±8.32 NS Yes 
 Incertae Sedis 
XIV 




3.40±3.07 2.69±3.42 2.76±3.10 1.95±1.55a 0.022 No 




1.85±4.58 0.77±1.53 0.68±1.28 0.59±0.80 NS Yes 
 Rikenellaceae 1.77±2.09 1.68±1.85 1.12±1.06 1.35±1.68 NS Yes 
 Veillonellaceae 1.59±1.13 1.52±1.19 1.86±1.19 1.97±1.60 NS Yes 











 Blautia 5.68±3.15 7.61±4.47 8.14±3.97b 8.61±4.32b 0.001 Yes 
 Ruminococcus 4.20±4.91 5.35±5.05 4.171±5.75 3.46±4.32 NS Yes 
 
Faecealibacterium 
2.82±2.38 3.06±2.29 3.86±3.22 3.86±3.19 NS Yes 
 Prevotella 2.79±8.89 1.99±6.24 3.34±9.84 2.02±6.30 NS Yes 
 Dorea 2.59±2.01 3.12±2.22 3.08±1.80 2.75±1.86 NS Yes 
 Parabacteroides 2.58±3.05 2.06±3.23 2.10±3.14 1.59±1.44 NS Yes 
 Roseburia 1.98±1.35 1.70±1.25 2.42±1.58 3.06±2.91e 0.01 Yes 
  Baseline BR BR+WGB WGB P-
value 
Confirmatio
n by linear 
model 
 Akkermansia 1.85±4.58 0.77±1.53 0.68±1.28 0.59±0.80 NS Yes 
 Coprococcus 1.82±2.09 1.91±2.08 1.47±2.22 1.35±1.78 NS Yes 
 Alistipes 1.76±2.08 1.67±1.85 1.11±1.05 1.34±1.67 NS Yes 
 Oscillibacter 1.27±1.04 1.24±1.00 1.08±0.83 0.96±0.61 NS Yes 
 Bifidobacterium 0.99±1.88 1.02±1.64 1.95±3.16 1.84±2.54d 0.011 No 
 Subdoligranulum 0.94±1.03 1.17±1.43 1.42±1.73 1.09±1.02 NS Yes 
 Dialister 0.75±1.17 0.60±0.89 0.94±1.21 1.14±1.69d 0.027 No 
 Odoribacter 0.26±0.24 0.28±0.35 0.28±0.41 0.15±0.18b 0.002 No 
              





0.15±0.14 0.13±0.18 0.15±0.24 0.07±0.10b 0.001 No 
 679, Eubacterium 
rectale, 94% 




 956, Roseburia 
faecis, 99% 




 770, Roseburia 
intestinalis, 100% 




 3, Blautia 
wexlerae, 100% 




 179-188, Blautia 
spp. 




2.48±2.67 2.75±3.27 3.65±3.45 4.83±3.98a,e,
g 
0.001 Yes 
Open in a separate window 
Abbreviations: BR, brown rice; NS, not significant; OUT, operational taxonomic unit; WGB, 
whole grain barley. 
Significantly different to baseline: aP<0.05, bP<0.01, cP<0.001. 
Significantly different to BR: dP<0.05, eP<0.01, fP<0.001. 
Significantly different to BR+WGB: gP<0.05. 
The increase in Firmicutes was more comprehensive and shifts in the abundance of several taxa 
were detected. All three dietary treatments increased the abundance of the genus Blautia and two 
operational taxonomic units within this genus (Table 2), although significance was only achieved 
when WGB was included in the treatment. Several compositional shifts were strictly associated 
with the consumption of WGB, namely the genera Roseburia, Bifidobacterium and Dialister and 
the species E. rectale, R. faecis and R. intestinalis (Table 2), and many of these taxa increased 
gradually with WGB intake. The linear regression model confirmed all of these significant 
changes except for the species Bifidobacterium, and Dialister. Other taxa clearly responded to 
WGB, but because of inter-individual variation, these shifts did not reach statistical significance. 
For example, Bacteroides coprocola, which was only detected in three subjects, showed a 10-
fold increase with WGB consumption in only two of the subjects (Supplementary Table S2). 
Although both whole grains led to an equivalent increase in the Firmicutes/Bacteroides ratio, no 
family or genus showed a significant increase for BR, suggesting that this test meal induced 
diverse alterations in the gut microbiome that are not consistent among subjects. 
No significant differences were detected in the amounts of short-chain fatty acids for any of the 
treatments. It is possible that an increase in short-chain fatty acids could not be detected in fecal 
samples they are for the most part absorbed in the gastrointestinal tract (Millet et al., 2010). 
Distribution of β-glucanase genes in human gut microbes 
WGB contains a high amount of β-glucans (14.1%), while none were detected in BR 
(Supplementary Table S1). In order to test if the ability to hydrolyze β-glucans could explain the 
specific shifts in the fecal microbiota induced through WGB, we investigated distribution of β-
glucanase genes in 112 strains originating from the human gut. This analysis revealed that β-
glucanase genes are present in a variety of gut bacterial species from a broad taxonomic range, 
including ten Bacteroides, four Bifidobacterium, three Collinsella, two Clostridium, two 
Coproccus, two Eubacterium, one Ruminococcus, two Roseburia, and one Akkermansia species 
(Supplementary Table S2). Of these species, only E. rectale, R. faecis and R. intestinalis were 
significantly increased through WGB, indicating that the mere presence of β-glucanase encoding 
genes does not predict the changes in community composition in response to the diet. 
Whole grain-induced metabolic and immunological changes 
The daily consumption of 60 g of whole grains for 4 weeks improved immunological and 
metabolic markers in the human subjects. The findings for the entire study population are shown 
in Supplementary Table S3, and differentiated by gender and body fat in Supplementary Tables 
S4 and S5. A significant decrease in plasma IL-6 levels for the BR+WGB treatment versus 
baseline values was detected (Figure 3a). Quantitatively, this reduction was highest in 
overweight subjects (Figure 3b). In women, all three treatments significantly reduced IL-6 
(Figure 3c). The linear model analysis confirmed the anti-inflammatory effect of whole grains 
and revealed a significant reduction of IL-6 for BR+WGB and WGB treatments (P<0.01, 
P<0.05). Despite not achieving statistical significance due to high inter-individual variation, hs-
CRP plasma levels were halved during the BR+WGB period compared with the baseline 
(Supplementary Tables S3-S5). 
 
 
Open in a separate window 
Figure 3 
Immunological and metabolic improvements induced through whole-grain consumption. Plasma 
IL-6 levels in the entire subject population (a), in overweight participants (b), and in females (c). 
Maximum postprandial glucose levels in the entire subject population (d) and overweight 
subjects (e) during the three treatments (BR, BR+WGB, WGB) and at baseline. *P< 0.05, **P< 
0.01, §P< 0.1. 
Whole-grain consumption significantly improved glucose and lipid metabolism. Postprandial 
peak glucose levels were significantly lowered in overweight subjects during the BR+WGB 
period (P<0.05), and the reduction approached significance in the entire study population 
(P<0.1) (Figures 3d and e). Fasting glucose levels were significantly decreased in women and 
overweight subjects, and in females, total cholesterol was significantly reduced (Supplementary 
Tables S4 and S5). 
Links between whole grain-induced metabolic improvements and fecal microbial 
community structure 
To determine whether effects of whole grains were related to the gut microbiome, a correlation 
analysis was performed between bacterial shifts and changes in the metabolic markers that 
occurred during the BR+WGB period. We focused the analysis on the BR+WGB treatment as it 
induced the most significant metabolic improvements (Figure 3). This analysis revealed that 
increases in the abundance of E. rectale were associated with improvements in the postprandial 
glucose and insulin response (Supplementary Figures S4A and SB). The association between E. 
rectale and maximum postprandial glucose levels approached significance (Supplementary 
Figure S4C). 
In addition, we categorized subjects into the three groups (terciles) according to the magnitude of 
the improvements in IL-6, hs-CRP, fasting glucose and glucose peak through BR+WGB. The 
baseline proportions of the bacterial groups between the three groups were compared. This 
analysis revealed that the gut microbiota of subjects with the highest improvement in IL-6 (3rd 
tercile) contained significantly higher percentages of Veillonellaceae (Figure 4a), and within this 
family, the genus Dialister (Figure 4b). Conversely, Coriobacteriaceae were significantly 
decreased in subjects with the highest improvement in IL-6 (Figure 4c). No significant 
differences in microbiome composition were detected between the terciles generated for hs-CRP, 





Abundance of specific taxa in subjects that showed differences in their IL-6 response to whole 
grains. Subjects were classified into terciles according to the magnitude of the change in plasma 
IL-6 levels induced by whole-grain consumption (BR+B treatment versus baseline). The 
proportions of bacterial taxa in fecal samples during the baseline were compared in the three 
terciles and significant differences existed in the proportions of Veillonellaceae (a), Dialister (b) 
and Coriobacteriaceae (c) in fecal samples during baseline. *P< 0.05, **P< 0.01. 
Gastrointestinal symptoms 
Self-reported symptoms diaries revealed that 60 g of WGB significantly increased all the 
gastrointestinal symptoms surveyed, especially flatulence, while 30 g caused only a slight 
increase in flatulence (Supplementary Table S6). The addition of BR to the diet did not result in 
any reported changes in symptoms. 
Go to: 
Discussion 
The metabolic and immunological benefits of whole grains have been shown in various studies 
(Fung et al., 2002; Behall et al., 2004; Jensen et al., 2004; Nilsson et al., 2006, 2008b), and a 
contribution of the gut microbiome to these effects has been suggested (North et al., 2009). 
However, the assessment of bacterial participation in these processes has been limited to 
hydrogen breath measurements, and the effects of whole grains on the gut microbiome structure 
have not been investigated. In this study, we showed that whole grains have a significant effect 
on the composition of the fecal microbiota that coincided with metabolic and immunological 
improvements in healthy human individuals. 
All whole-grain test meals caused an increase in community diversity within the subjects, driven 
by an increase in evenness of bacterial species. Therefore, WGB and BR seem to differ in their 
effects on the gut microbiota when compared with prebiotics and dietary fibers, which have not 
been shown to increase community diversity (Martínez et al., 2010; Davis et al., 2011; Van den 
Abbeele et al., 2011). These differences might be due to compositional complexity of whole 
grains, which contain a variety of carbohydrates, potentially affecting a wider scope of bacterial 
taxa. Interestingly, a higher microbial diversity in fecal samples was also observed in children 
from Burkina Faso, who consumed a diet high in whole grains, legumes and vegetables, when 
compared with Europeans (De Filippo et al., 2010). In addition, weaning in human infants leads 
to a drastic increase in diversity likely caused by the incorporation of more diverse arrays of 
dietary carbohydrates (reviewed in Koropatkin et al., 2012). Therefore, it appears that bacterial 
diversity in the gut can be increased by providing a broader range of undigestible substrates, and 
our findings showed that this can be achieved by intake of whole grains. 
This study revealed shifts in the fecal microbiota that were induced by both BR and WGB, while 
others were specific to WGB intake. Both whole grains increased the Firmicutes/Bacteroidetes 
ratio and the abundance of the genus Blautia. The overall shift in microbiota structure in favor of 
an expansion of Firmicutes could be the result of an increased carbohydrate intake (Duncan et 
al., 2008). However, in a previous study, we did not observe an increase in the 
Firmicutes/Bacteroidetes ratio with the consumption of crackers containing resistant starches 
(Martínez et al., 2010), although the dose of carbohydrates and fiber in these crackers exceeded 
that of the whole-grain test meals. Interestingly, a decrease of Bacteroides was also shown to be 
associated with a long-term consumption of diets rich in whole grains, dietary fibers and 
vegetables in African children and US individuals (De Filippo et al., 2010; Wu et al., 2011). 
These and our findings suggest that other components included in whole grains and other plant-
derived food products might influence community structure at the phylum level, specifically 
decreasing Bacteroidetes. The reason for the increase in the genus Blautia through whole grains 
might be due to a syntrophic effect. Blautia species are acetogenic and might benefit from the 
production of hydrogen, which is a product of glycan fermentation, and, therefore, likely induced 
by whole grain consumption (Nakamura et al., 2010; Koropatkin et al., 2012). 
We detected several bacterial taxa that displayed a specific increase with WGB, several with a 
clear dose response. This is likely due to its high content of β-glucans. Accordingly, the bacteria 
that specifically responded to WGB harbor genes encoding for β-glucanases and utilize the 
substrate in vitro (Hughes et al., 2008; Tasse et al., 2010). However, the in vivo findings cannot 
solely be explained based on functional and genomic attributes of community members, as 
Bacteroides species decreased during WGB consumption, but possess β-glucanase genes and can 
utilize β-glucans in vitro (Crittenden et al., 2002; Tasse et al., 2010; Zhao and Cheung, 2011). A 
possible explanation for the in vivo findings could entail preferences towards distinct β-glucan 
structures and molecular weights. The β(1–4) to β(1–3) linkage ratio in barley is 2.3-3, while 
Bacteroides species have been shown to especially possess β(1–3)-glucanase activity (Salyers et 
al., 1977). Moreover, barley-derived β-glucan fractions of high molecular weight have also been 
shown to be poorly fermented by Bacteroides (Hughes et al., 2008). However, previous human 
trials with prebiotics and resistant starches have also revealed that the ability of a species to 
utilize substrates in vitro does not predict population shifts in vivo (Martínez et al., 2010; Davis 
et al., 2011; Koropatkin et al., 2012). Therefore, although the findings obtained suggest that β-
glucans are the main cause for the shifts in composition induced by WGB, the exact mechanisms 
by which these changes are restricted to only a small number of taxa are likely to be due to 
competitive interactions. 
A main objective of this study was to determine whether the effects of whole grains on the gut 
microbiome are associated with physiological benefits. The whole grains used in our study led to 
immunological and metabolic improvements, especially when BR+WGB was consumed. Plasma 
IL-6 was reduced, and a tendency for a decrease in plasma hs-CRP was detected. In addition to 
this anti-inflammatory effect, an improvement in the glycemic response during BR+WGB 
treatment was detected. Our findings are in agreement with previous research that established the 
immunological and metabolic benefits of whole grains (Casiraghi et al., 2006; Kallio et al., 
2008; Nilsson et al., 2008b; Rosén et al., 2011). Most importantly, inflammation has been 
identified as a main cause of metabolic disorders (Hotamisligil, 2006), and the anti-inflammatory 
effect could provide a mechanism by which whole grains improve glucose metabolism. 
The anti-inflammatory effect of whole grains might be mediated through its effect on the gut 
microbiota. A remarkable positive correlation between LBP and hs-CRP was identified in our 
study population, supporting a link between bacterial lipopolysaccharide and systemic 
inflammation. The associations of these markers with body-fat support the hypothesis that 
endotoxemia could contribute to obesity (Cani et al., 2007; Delzenne and Cani, 2011). WGB led 
to an increase of bacterial taxa such as bifidobacteria and Roseburia, which have been suggested 
to affect immune/inflammatory and metabolic functions in animal models (Cani et al., 2008; 
Neyrinck et al., 2011). Although one could envision that these shifts might underlie the anti-
inflammatory effect of whole grains, no significant correlations between these taxa and 
inflammatory markers were observed. However, shifts in the abundance of E. rectale induced 
through the BR+WGB diet correlated with decreased postprandial glucose and insulin responses. 
This organism produces butyrate, which might contribute to the immunological benefits of whole 
grain consumption through its anti-inflammatory effects. 
Interestingly, compositional differences at baseline were detected in the gut microbiome of 
subjects that differed in the magnitude of their anti-inflammatory response to whole grains. 
Subjects with the greatest reduction in plasma IL-6 concentration had significantly higher 
proportions of Dialister and a lower abundance of Coriobacteriaceae. These bacterial groups 
have been linked to chronic inflammation in previous studies. D. invisus and Coriobacteriaceae 
have been shown to be reduced and increased in patients with Crohn's disease and colitic mice, 
respectively (Clavel et al., 2009; Würdemann et al., 2009; Willing et al., 2010; Joossens et al., 
2011). The association of Dialister and Coriobacteriaceae with IL-6 response suggests that these 
taxa may condition the capability of an individual to be immunologically responsive to whole 
grains. 
Before the start of the treatments, associations between bacterial groups, inflammatory state and 
host metabolism were observed (Figure 3). Ruminococcaceae negatively correlated with markers 
of inflammation and were more dominant in normoweight individuals. In addition, Bacteroidetes 
positively correlated with HDL cholesterol. These observations could result from an impact of 
these taxa on host physiology, and these associations provide a rationale to develop dietary 
strategies that target Ruminococcaceae and Bacteroidetes to improve human metabolic and 
immunological functions. However, host physiology (inflammatory state, cholesterol/bile acid 
metabolism) might also shape the microbiome composition. If systemic inflammation and 
cholesterol metabolism impact levels of Ruminococcaceae and Bacteroidetes, respectively, then 
these interactions could explain the discrepancies related to an altered microbiome in obese 
versus normoweight individuals (Ley et al., 2006; Duncan et al., 2008; Schwiertz et al., 2010). 
Not obesity per se, but the associated inflammatory and metabolic aberrations could shape 
microbiome composition and might cause variable and more complex patterns of dysbiosis. 
This study has provided novel information about the relationship between whole grains, the gut 
microbiota and host metabolism. Whole grain-induced alterations in the characteristics and 
composition of the fecal microbiota coincided with immunological and metabolic benefits, and 
the clear associations between the reduction of IL-6 and the presence of certain bacterial taxa 
(Dialister, Coriobacteriaceae) indicate an important functional role of gut bacteria in the 
physiologic effects of whole grains. 
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Materials and Methods 
 
Subjects 
Interviews were conducted with the volunteers to explain the protocol, determine 
whether they met the inclusion criteria, and record demographic data (age and 
gender).  Exclusion criteria were treatment with antibiotics within 3 months prior 
to the beginning of the study or throughout its duration, being vegetarian, 
exercise of more than 2 h weekly, a history of a chronic gastrointestinal disorder, 
and the use of antihypertensive or lipid-lowering medications. Twenty-nine 
healthy adults were recruited to participate in this study. One female subject was 
excluded during the study as she required antibiotic treatment. Prior to the 
beginning of the study, training sessions were held to explain the protocol to the 
subjects.  
 
Participants were instructed to incorporate the whole grains to their regular diet. 
Other instructions included withholding from strenuous physical activity and 
alcohol consumption on the day prior to blood drawing. Compliance with the 
dietary treatments was encouraged by meeting with the subjects on a weekly 
basis, on which occasions symptom diaries were collected and a bag with 7 daily 




Prowashonupana (Sustagrain® Barley Quick Flakes, ConAgra Mills) is a waxy, 
hulless barley variety differing from standard barley in terms of its composition.  
Prowashonupana contains exceptionally high levels of total dietary fiber (30%), 
almost half being accounted for by β-glucan, and low levels of starch (<30%).  
Brown rice has high amounts of soluble starch (around 75%) and small amounts 
of total dietary fiber (around 7%). The processing of the barley flakes was as 
follows, cleaned grain kernels were roller cut and steam treated at 100.5°C for 40 
min to ensure microbiological safety and passed through flaking rolls to reduce 
the pieces to a thickness of 0.020 ± 0.002 inches.  The flakes were then cooled 
down to room temperature, seized, screened and packaged. The brown rice 
(Insta Grains® Brown Rice Flakes, Briess) was used as provided by the 
manufacturer.  It is currently unknown how the processing conditions of both 
whole grains affect their functionality when compared to the unprocessed grains.  
 
Digestible and resistant starches in the two flakes were measured in the products 
(K-RSTAR, Megazyme, Ireland), as well as β-glucans (K-BGLU, Megazyme, 
Ireland), and total dietary fiber (Andersson et al., 2009; AACC International, 
2011). The nutritional data of the flakes is presented in Table S1.  
 
DNA extraction from fecal samples 
Fecal homogenates were transferred to bead beating tubes (Biospec products, 
USA) containing zirconium beads (300 mg). Homogenates were centrifuged 
(8,000×g for 5 min at room temperature) and the bacterial cell pellets were 
washed twice by re-suspension in ice-cold PBS. 100 µl of lysis buffer (200 mM 
NaCl, 100 mM Tris, 20 mM EDTA, 20 mg/ml Lysozyme, pH 8.0) containing 20 
mg/ml of Lysozyme (Sigma-Aldrich) were added, and enzymatic lysis was 
conducted at 37°C for 30 min. 1.6 ml of buffer ASL  from QIAamp DNA Stool Mini 
Kit (Qiagen, Germany) was added to each sample, after which the samples were 
mechanically homogenized in a MiniBeadbeater-8 (BioSpec Products, USA) for 2 
min at maximum speed. DNA was purified from 1.2 ml of the resulting 
supernatant with the QIAamp DNA Stool Mini Kit following the manufacturer's 
instructions. 
 
Compositional analysis of the fecal microbiota by pyrosequencing 
Sequences were binned by primer barcodes using QIIME (Caporaso et al., 
2010). Sequences that were shorter than 300 bp or longer than 550 bp, 
contained one or more ambiguous nucleotides, had one or more mismatches to 
the primer or barcode, had an average quality scores below 25, or contained 
homopolymer runs over 6 bp, were removed. Chimeras were removed using the 
Blast Fragments Algorithm included in QIIME.  
 
OTU picking was performed by aligning sequences using the RDP Infernal 
Alignment tool and clustered with the Complete Linkage Clustering algorithm 
(RDP).  As current OTU picking algorithms tend to generate too many clusters 
(Ghodsi et al., 2011), abundance of OTUs identified to be associated with host 
phenotypes or dietary treatments were confirmed using BLASTn.  For this 
purpose, 5 representative sequences per OTU were taxonomically assigned and 
aligned by ClustalW within their respective phylum. A distance matrix was 
generated and phylogenetic trees (one per phylum) were constructed using the 
Neighbor-joining algorithm (MEGA 4.0) (Tamura et al., 2007).  OTUs were 
assigned visually as clusters within the phylogenetic trees, and membership was 
confirmed by sequence comparisons and restricted to sequences with >97% 
similarity.  Consensus sequences were generated for each OTU. To quantify 
each OTU, a local database was created in BioEdit (Hall, 1999) with all the 
sequences.  BLASTn with >97% similarity and >95% length overlap was used to 
determine the number of sequences belonging to individual OTUs. OTUs that 
shared a majority of their sequences were merged.   
 
Genome queries for β-glucanase activity 
 
The web-based Integrated Microbial Genomes (IMG) database of the Joint Genome 
Institute (JGI) was used to identify gut organisms with beta-glucanase function. The 
following bacteria were included: Bacteroides caccae ATCC 43185, Bacteroides 
coprocola M16, Bacteroides dorei 5_1_36/D4, Bacteroides dorei DSM 17855, 
Bacteroides eggerthii 1_2_48FAA, Bacteroides eggerthii DSM 20697, 
Bacteroides finegoldii DSM 17565, Bacteroides fragilis 3_1_12, Bacteroides 
fragilis 638R, Bacteroides fragilis NCTC 9343, Bacteroides fragilis YCH46, 
Bacteroides intestinalis 341, Bacteroides ovatus 3_8_47FAA, Bacteroides ovatus 
ATCC 8483, Bacteroides ovatus SD CC 2a, Bacteroides ovatus SD CMC 3f, 
Bacteroides stercoris ATCC 43183, Bacteroides thetaiotaomicron VPI-5482, 
Bacteroides uniformis ATCC 8492, Bacteroides vulgatus ATCC 8482; 
Bacteroides vulgatus PC510, Bacteroides xylanisolvens SD CC 1b, Bacteroides 
xylanisolvens XB1A, Bifidobacterium adolescentis ATCC 15703, Bifidobacterium  
adolescentis L2-32, Bifidobacterium catenulatum DSM 16992, Bifidobacterium 
longum DJO10A, Bifidobacterium longum NCC2705, Bifidobacterium longum 
subps. infantis 157F-NC, Bifidobacterium longum subps. infantis ATCC 16697, 
Bifidobacterium longum subps. infantis JCM 1217, Bifidobacterium longum 
subsp. longum ATCC 55813, Bifidobacterium longum subsp. longum BBMN68, 
Bifidobacterium longum subsp. longum CCUG 52486, Bifidobacterium longum 
subsp. longum F8, Bifidobacterium longum subsp. longum JDM301, 
Bifidobacterium longum subsp. longum KACC 91563, Bifidobacterium 
pseudocatenulatum DSM 20438, Blautia hansenii VPI C7-24, Blautia 
hydrogenotrophica DSM 10507, Bryantella formatexigens I-52, Butyrivibrio 
crossotus DSM 2876, Clostridiales sp. SM4/1, Clostridiales sp. 1_7_47FAA, 
Clostridiales sp. SS3/4, Clostridiales sp. SSC/2, Clostridium bolteae ATCC BAA-
613, Clostridium butyricum 5521, Clostridium butyricum E4, Clostridium leptum 
DSM 753, Clostridium ramosum VPI 0427, Clostridium sp. M62/1, Clostridium 
spiroforme DSM 15579, Collinsella aerofaciens ATCC 25986, Collinsella 
intestinalis DSM 13280, Collinsella stercoris DSM 13279, Coprococcus comes 
ATCC 27758, Coprococcus eutactus ATCC 27759, Dialister invisus DSM 15470, 
Dorea formicigenerans ATCC 27755, Dorea longicatena DSM 13814, 
Eggerthella lenta VPI 0255, Enterococcus fecalis ATCC 29200, Enterococcus 
fecalis ATCC 4200, Eubacterium biforme DSM3989, Eubacterium cylindroides 
T2-87, Eubacterium eligens ATCC 27750, Eubacterium hallii DSM 3353, 
Eubacterium limosum KIST612, Eubacterium rectale ATCC 33656, Eubacterium 
rectale DSM 17629, Eubacterium rectale M104/1, Eubacterium ventriosum ATCC 
27560, Faecalibacterium prausnitzii KLE1255, Faecalibacterium prausnitzii A2-
165, Faecalibacterium prausnitzii L2-6, Faecalibacterium prausnitzii M21/2, 
Faecalibacterium prausnitzii SL3/3, Lachnospiraceae 1_1_57FAA, 
Lachnospiraceae 1_4_56FAA, Lachnospiraceae 2_1_46FAA, Lachnospiraceae 
2_1_58FAA, Lachnospiraceae 3_1_46FAA, Lachnospiraceae 3_1_57FAA, 
Lachnospiraceae 4_1_37FAA, Lachnospiraceae 5_1_37FAA, Lachnospiraceae 
6_1_63FAA, Lachnospiraceae 9_1_43BFAA, Lachnospiraceae sp 5_1_63FAA, 
Lachnospiraceae 8_1_57FAA, Olsenella uli DSM 7084, Odoribacter 
splanchnicus DSM 20712, Parabacteroides distasonis ATCC 8503, 
Parabacteroides merdae ATCC 43184, Parabacteroides sp. D13, 
Phascolarctobacterium sp YIT 12067, Prevotella bryantii B14, Roseburia 
intestinalis L1-82, Roseburia intestinalis M50/1, Roseburia intestinalis XB6B4, 
Roseburia inulinivorans DSM 16841, Ruminococcaceae bacterium D16, 
Ruminococcus bromii L2-63, Ruminococcus gnavus ATCC 29149, 
Ruminococcus lactaris ATCC 29176, Ruminococcus obeum A2-162, 
Ruminococcus obeum ATCC 29174, Ruminococcus torques ATCC 27756, 
Ruminococcus torques L2-14, Slackia exigua ATCC 700122, Slackia 
heliotrinireducens DSM 20476, Turicibacter sanguinis PC909. 
 
Short chain fatty acid determination 
SCFAs were determined based on approaches described by Campbell and 
coworkers (1997), with slight modifications. Undiluted fecal samples were 
removed from storage at -80°C and thawed on ice, and 0.4 g were diluted in 2.8 
ml water containing 5-10 mM 4-methylvaleric acid and vortexed. 0.4 ml of 25% 
(w/v) metaphosphoric acid was added and the sample was vortexed again, 
followed by centrifugation for 20 min at 15,000 x g. The supernatant was stored 
overnight at -20°C. Samples were thawed and centrifuged in the same conditions 
as before. SCFA were quantified by gas chromatography (Perkin Elmer Clarus 
with Perkin Elmer Elite-FFAP column) in a 4 μl injection volume, and the data 
was analyzed with appropriate software (TotalChrom, Perkin Elmer, USA). 
Moisture quantification in the fecal samples was done as follows. Approximately 
0.2 g of feces was introduced into a plastic tube with a small perforation in its cap 
and frozen overnight at -20°C. Samples were freeze dried for at least 36 hours 
until stable weight of the sample was achieved, and dry weight was calculated. 
SCFA were expressed on a dry basis. 
 
Statistics 
Correlations between host parameters and bacterial populations were assessed 
by Pearson’s correlation test (GraphPad Prism v5.0). Graphs were generated for 
parameters that showed significant correlations and were visually inspected. If 
the removal of one single data-point caused the association to become non-
significant, the data point was considered an outlier and removed.  
Associations between inflammatory markers and members of the gut microbiome 
were further analyzed with the following linear models: 
 
Iijt = β0 + β1Fat + β2Gender + β3Age + β4T2 + β5T3 + β6T4 (1) 
M
 
hjt = β0 + β1Fat + β2Gender + β3Age + β4T2 + β5T3 + β6T4 (2) 
ijt is the inflammatory marker i for subject j in treatment t, i=1,2,3; j=1…28; 
hjt is the inflammatory marker h for subject j in treatment t, h=1,…,80; j=1…28; 
t=1,2,3,4; Fat indicates the percent body fat; Gender is a binary variable that 
takes values of 0 if the subject is female and 1 otherwise; Age is the age of 
subject in years; T2 is a binary variable that assigns 1 if the treatment is 30 
grams of B and BR each and 0 otherwise; T3 is a binary variable that assigns 1 if 
the treatment is 60 grams of B and 0 otherwise; T4 is a binary variable that 
assigns 1 if the treatment is 60 grams of BR and 0 otherwise; and T1 represents 
no treatment and is left out of the models as the base.  Fixed effects and random 
effects methods were used to estimate models (1) and (2).  Chi-square estimates 
that measure the heterogeneity of the responses clustered by subject, were used 
as the criterion for choice between fixed and random effects estimation methods. 
For the models with Chi-square values associated with P < 0.1, random effects 
method was chosen. 
 
Because hs-CRP concentrations >10 mg/l in plasma are indicative of acute 
inflammation unrelated to cardiovascular disease risk (Pearson et al., 2003). 
Therefore, 4 samples from 4 different subjects were excluded from the analysis. 
If the same samples also displayed abnormally high values of LBP or IL-6 levels, 
these data points were also considered outliers and removed. 2 and 3 samples 
were excluded from LBP and IL-6 analysis, respectively. One subject was 
excluded from the analysis of glucose parameters as incomplete data was 
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a Nutrient composition as provided by the manufacturers except when specifically noted. 
b Measured with K-RSTAR Megazyme kit. (Expressed as dry basis). 
C Measured according to AACCI Approved Method 32-25.01 with modifications from Andersson et al. 
1999). (Expressed as dry basis). (





Table S2. List of bacterial species possessing β-glucanase genes and/or 
that responded to whole grain barley. Bacterial genomes containing β-
glucanase genes were identified using the Integrated Microbial Genomes system 
(IMG). The number and types of β-glucanases are indicated for the individual 
species. The number of subjects in which the species was detected and the 
direction of the shifts in response to WGB intake are presented. Abundances of 
species as a percentage of total fecal microbiota are also shown (mean ± SD). 









Abundance (% of total microbiota) P-value 
(ANOVA) Baseline 
(mean ± SD) 
BR 
(mean ± SD) 
BR+WGB 
(mean ± SD) 
WGB 
(mean ± SD) 
Akkermansia muciniphila 2 β-glucanase precursor 10 10 no pattern 0.84 ± 1.82 0.57 ± 1.3 0.34 ± 0.86 0.41 ± 0.66 NS 
Bacteroides caccae 7 β-glucanase/β-glucanase synthase 17 17 no pattern 0.2 ± 0.75 0.09 ± 0.21 0.13 ± 0.31 0.13 ± 0.43 NS 
Bacteroides coprocola 4 endoglucanase 2 β-glucanase/β-glucanase synthase 3 
2 ↑  
1 no pattern 0.37 ± 1.52 0.14 ± 0.5 1.06 ± 3.73 1.24 ± 4.68 NS 
Bacteroides dorei 1 β-glucanase 2 β-glucanase/β-glucanase synthase 24 24 no pattern 1.88 ± 3.81 1.60 ± 2.90 1.37 ± 2.75 1.34 ± 2.84 NS 
Bacteroides finegoldii 2 β-glucanase/β-glucanase synthase 4 4 no pattern 0.04 ± 0.2 0.06 ± 0.19 0.06 ± 0.33 0.02 ± 0.08 NS 
Bacteroides fragilis 9 β-glucanase precursor 3 putative β-glucanase precursor 18 
1 ↓ 
17 no pattern 2.68 ± 8.12 1.81 ± 6.04 1.60 ± 5.05 1.21 ± 4.56 NS 
Bacteroides intestinalis 2 β-glucanase/β-glucanase synthase6 endoglucanase 25 
3 ↑  
22 no pattern 0.32 ± 0.55 0.93 ± 2.66 0.38 ± 0.69 0.47 ± 0.76 NS 
Bacteroides ovatus 2 β-glucanase/β-glucanase synthase6 endoglucanase ND 
Bacteroides thetaiotamicron 3 β-glucanase precursor 2 endoglucanase E precursor 25 25 no pattern 0.57 ± 0.79 0.72 ± 1.38 0.52 ± 0.98 0.40 ± 0.52 NS 
Bacteroides uniformis 1 β-glucanase/β-glucanase synthase8 endoglucanase 26 
1 ↑ 
3 ↓ 
22 no pattern 
4.55 ± 4.55 3.34 ± 3.3 2.77 ± 3.38 3.57 ± 4.59 NS 
Bacteroides eggerthii 2 endoglucanase 7 1 ↑  6 no pattern 0.35 ± 1.39 0.36 ± 1.03 0.32 ± 1.15 0.33 ± 0.97 NS 
Blautia wexlerae No matches found 28 
6 ↑ 
1 ↓ 
11 no pattern 
1.07 ± 0.78 1.58 ± 1.11 1.49 ± 0.98 1.82 ± 1.14¶¶¶* < 0.0001 
Blautia hydrogenotrophica No matches found 4 4 no pattern 0.00 ± 0.01 0.00 ± 0.01 0.00 ± 0.02 0.00 ± 0.01 NS 
Blautia coccoides No matches found 7 7 no pattern 0.01 ± 0.02 0.00 ± 0.01 0.00 ± 0.01 0.01 ± 0.02 NS 
Blautia producta No matches found 4 4 no pattern 0.01 ± 0.03 0.00 ± 0.01 0.00 ± 0.01 0.00 ± 0.01 NS 
Blautia hansenii No matches found 5 5 no pattern 0.10 ± 0.26 0.05 ± 0.16 0.18 ± 0.91 0.08 ± 0.34 NS 
Blautia spp. (Ruminococccus 
obeum) 1,3-beta-glucosidase 14 
4 ↑  
10 no pattern 1.81 ± 1.13 2.38 ± 1.69 2.75 ± 1.75
¶ 2.80 ± 2.04¶¶ 0.006 
Bifidobacterium adolescentis 2 putative β-1,3-endoglucanase 2 endoglucanase 14 
2 ↑  
12 no pattern 0.22 ± 0.42 0.36 ± 0.83 0.64 ± 1.3 0.48 ± 1.08 NS 
Bifidobacterium angulatum 2 endoglucanase ND 
Bifidobacterium longum 1 putative β-1,3-exoglucanase 2 endoglucanase 17 
1 ↑  
16 no pattern 0.16 ± 0.42 0.17 ± 0.50 0.18 ± 0.33 0.23 ± 0.50 NS 
Bifidobacterium 
pseudocatenulatum 4 endoglucanse 7 7 no pattern 0.07 ± 0.22 0.14 ± 0.65 0.08 ± 0.24 0.07 ± 0.20 NS 
Clostridium butyricum 7 endoglucanase 4 4 no pattern 0.01 ± 0.03 0.00 ± 0.01 0.00 ± 0.01 0.00 ± 0.01 NS 
Clostridium ramosum 2 β-glucanase/β-glucanase synthase2 endoglucanase ND 
Collinsella aerofaciens 2 endoglucanase 17 17 no pattern 0.08 ± 0.22 0.14 ± 0.28 0.1 ± 0.19 0.08 ± 0.18 NS 
Collinsella intestinalis 2 endoglucanase ND 
Collinsella stercoris 2 endoglucanase ND 
Coprococcus comes 2 endoglucanase 25 1 ↑  24 no pattern 0.29 ± 0.38 0.35 ± 0.42 0.33 ± 0.48 0.29 ± 0.45 NS 
Coprococcus eutactus 1 β-glucanase/β-glucanase synthase8 endoglucanase 13 
1 ↑  
12 no pattern 0.68 ± 1.23 0.64 ± 1.23 0.62 ± 1.29 0.75 ± 1.35 NS 
Dialister invisus No matches found 0.52 ± 0.97 0.41 ± 0.72 0.56 ± 0.86 0.81 ± 1.41 
Eubacterium eligens 1 putative endoglucanase 14 2 ↑  12 no pattern 0.22 ± 0.42 0.36 ± 0.83 0.64 ± 1.3 0.48 ± 1.08 NS 
Eubacterium rectale 1 endo-1,4-β-glucanase 28 14 ↑  14 no pattern 2.48 ± 2.67 2.75 ± 3.27 3.65 ± 3.45 4.83 ± 3.98
¶ŦŦ* 0.001 
Roseburia inulinivorans 1 endo-1,4-β-glucanase 28 1 ↑  27 no pattern 0.25 ± 0.3 0.21 ± 0.32 0.14 ± 0.24 0.16 ± 0.18 NS 
Roseburia faecis Not in database 27 10 ↑  17 no pattern 0.12 ± 0.17 0.06 ± 0.07 0.26 ± 0.31 0.53 ± 0.92
¶¶ŦŦŦ < 0.0001 
Roseburia intestinalis 5 endo-1,4-β-glucanase 28 9 ↑  19 no pattern 0.09 ± 0.12 0.04 ± 0.05 0.17 ± 0.18
Ŧ 0.30 ± 0.42¶ŦŦŦ < 0.0001 
ND: Not detected; NS: Not significant. 
Table S3. Treatment effect on metabolic and immunological markers for all 
subjects. Metabolic data of the 28 participants, at baseline and at the end of the 
4-week dietary treatments (BR, BR+WGB, WGB). Values are presented as mean 
± SD. 
 Overall  
  Baseline BR BR+WGB WGB P-value 
Cholesterol      
Total cholesterol (mmol/l) 4.86 ± 1.15 4.76 ± 0.79 4.56 ± 0.89 4.89 ± 0.94 NS 
Non-HDL (mmol/l) 3.09 ± 1.04 3.15 ± 0.84 3.00 ± 0.85 3.32 ± 0.94 NS 
HDL (mmol/l) 1.63 ± 0.43 1.60 ± 0.37 1.55 ± 0.45 1.57 ± 0.36 NS 
Plasma glucose      
Fasting (mmol/l) 5.15 ± 0.73 4.87 ± 0.49 4.81 ± 0.39 4.81 ± 0.50 NS 
AUC ([mmol/l]2) 784 ± 184 763 ± 164 746 ± 132 770 ± 179 NS 
Max. peak (mmol/l) 9.08 ± 2.78 8.58 ± 2.02 7.92 ± 1.46 8.19 ± 2.35 < 0.1 
Plasma insulin      
Fasting (μUI/ml) 6.77 ± 1.96 6.60 ± 2.13 6.51 ± 2.02 7.03 ± 2.07 NS 
AUC ([μUI/ml]2) 3463 ± 1523 3606 ± 1520 3333 ± 1035 3540 ± 1481 NS 
Max. peak (μUI/ml) 44.08 ± 19.19 44.70 ± 19.56 42.86 ± 14.49 45.13 ± 21.61 NS 
Inflammatory markers      
IL-6 (pg/ml) 1.68 ± 1.36 1.21 ± 0.99 0.90 ± 0.45* 1.12 ± 0.63 0.0295 
Hs-CRP (mg/L) 1.60 ± 2.23 1.33 ± 1.65 0.95 ± 1.23 1.36 ± 1.88 NS 
LBP (μg/ml) 14.41 ± 19.65 14.39 ± 2.09 13.23 ± 19.04 13.78 ± 18.30 NS 
*P < 0.05 compared to Baseline. 
Table S4. Treatment effect on metabolic and immunological markers in the subjects according to gender. 
Metabolic data of the female and male volunteers, at baseline and at the end of the 4-week dietary treatments (BR, 
BR+WGB, WGB). Values are presented as mean ± SD. 
 Males Females 
  Baseline BR BR+WGB WGB P-value Baseline BR BR+WGB WGB P-value 
Cholesterol           
Total cholesterol (mmol/l) 4.42 ± 1.11 4.59 ± 0.85 4.31 ± 0.91 4.46 ± 0.89 NS 5.02 ± 1.14 4.87 ± 0.76 4.73 ± 0.87 5.15 ± 0.89 0.0342 
Non-HDL (mmol/l) 2.78 ± 0.74 3.01 ± 0.96* 2.90 ± 0.93 3.08 ± 0.82 0.0327 3.29 ± 1.16 3.24 ± 0.78 3.06 ± 0.83 3.47 ± 1.00 NS 
HDL (mmol/l) 1.30 ± 0.28 1.41 ± 0.30 1.33 ± 0.31 1.23 ± 0.24 NS 1.84 ± 0.37 1.73 ± 0.36 1.69 ± 0.48 1.76 ± 0.25  NS 
Plasma glucose           
Fasting (mmol/l) 5.14 ± 0.72 5.10 ± 0.64 4.91 ± 0.39 4.86 ± 0.34 NS 5.15 ± 0.76 4.72 ± 0.29 4.75 ± 0.40 4.77 ± 0.59 0.0344 
AUC ([mmol/l]2) 860 ± 232 851 ± 143 762 ± 166 857 ± 180 NS 739 ± 138 706 ± 155 735 ± 110 718 ± 162 NS 
Max. peak (mmol/l) 10.13 ± 3.25 10.08 ± 1.67 8.21 ± 1.80 8.99 ± 2.37 < 0.1 8.40 ± 2.27 7.61 ± 1.61 7.74 ± 1.23 7.66 ± 2.26 NS 
Plasma insulin           
Fasting (μUI/ml) 6.63 ± 1.75 5.93 ± 1.90 6.38 ± 1.80 6.05 ± 2.12 NS 6.85 ± 2.12 7.04 ± 2.22 6.60 ± 2.20 7.66 ± 1.83 NS 
AUC ([μUI/ml]2) 3436 ± 1787 3816 ± 1704 3399 ± 1086 3600 ± 1586 NS 3480 ± 1405 3483 ± 1442 3294 ± 1037 3505 ± 1465 NS 
Max. peak (μUI/ml) 42.76 ± 20.55 48.63 ± 19.14 41.46 ± 12.37 48.54 ± 22.37 NS 44.93 ± 18.86 42.15 ± 19.98 43.76 ± 16.01 42.92 ± 21.50 NS 
Inflammatory markers           
IL-6 (pg/ml) 1.18 ± 0.81 1.42 ± 1.35 1.99 ± 3.63 1.09 ± 0.58 NS 2.01 ± 1.58 1.16 ± 0.83* 1.10 ± 0.86** 1.67 ± 2.39* 0.0028 
Hs-CRP (mg/L) 0.35 ± 0.22 0.92 ± 1.26 0.31 ± 0.24 0.76 ± 1.07 NS 2.35 ± 2.56 1.57 ± 1.85 1.33 ± 1.43 1.72 ± 2.19 NS 
LBP (μg/ml) 4.76 ± 2.96 6.50 ± 5.48 4.42 ± 2.22 6.19 ± 4.09 NS 20.44 ± 23.19 19.32 ± 25.62 18.73 ± 22.74 18.52 ± 22.04 NS 




*P < 0.01 compared to Baseline. 
 
Table S5. Treatment effect on metabolic and immunological markers in normoweight and overweight subjects. 
Metabolic data of normoweight and overweight, at baseline and at the end of the 4-week dietary treatments (BR, 
BR+WGB, WGB). Values are presented as mean ± SD. 
 Overweight Normoweight 
  Baseline BR BR+WGB WGB P-value Baseline BR BR+WGB WGB P-value 
Chol  esterol           
Total cholesterol (mmol/l) 4.84 ± 1.26 4.84 ± 0.86 4.51 ± 0.89 5.03 ± 1.05 NS 4.75 ± 1.07 4.69 ± 0.75 4.61 ± 0.92 4.77 ± 0.84 NS 
Non-HDL (mmol/l) 3.24 ± 1.21 3.35 ± 0.97 3.12 ± 0.90 3.52 ± 1.05 NS 2.94 ± 0.85 2.98 ± 0.71 2.89 ± 0.83 3.14 ± 0.83 NS 
HDL (mmol/l) 1.61 ± 0.45 1.47 ± 0.32 1.37 ± 0.40 1.51 ± 0.35 NS 1.65 ± 0.42 1.72 ± 0.38 1.71 ± 0.45 1.62 ± 0.37 NS 
Plasma glucose           
Fasting (mmol/l) 5.37 ± 0.93 4.87 ± 0.45* 4.88 ± 0.37 4.88 ± 0.42 0.0231 4.94 ± 0.40 4.87 ± 0.54 4.75 ± 0.42 4.74 ± 0.57 NS 
AUC ([mmol/l]2) 867 ± 184 800 ± 187 774 ± 128 811 ± 160 NS 707 ± 153 730 ± 140 720 ± 135 731 ± 192 NS 
Max. peak (mmol/l) 9.66 ± 2.14 8.53 ± 2.11 7.99 ± 1.32* 8.43 ± 1.79 0.0428 8.58 ± 3.09 7.86 ± 1.62 7.98 ± 2.80 8.63 ± 2.01 NS 
Plasma  insulin           
Fasting (μUI/ml) 6.93 ± 1.70 7.10 ± 2.53 6.82 ± 1.78 7.60 ± 1.58 NS 6.62 ± 2.22 6.17 ± 1.69 6.24 ± 2.24 6.54 ± 2.36 NS 
AUC ([μUI/ml]2) 3730 ± 1677 3952 ± 1665 3249 ± 1128 3804 ± 1482 NS 3216 ± 1382 3284 ± 1354 3411 ± 978 3295 ± 1493 NS 
Max. peak (μUI/ml) 48.39 ± 19.92 50.23 ± 22.63 43.19 ± 16.16 49.94 ± 21.17 NS 40.34 ± 18.38 39.90 ± 15.67 42.57 ± 13.45 40.96 ± 26.83 NS 
Inflammatory markers           
IL-6 (pg/ml) 2.03 ± 1.32 1.64 ± 1.27 0.97 ± 0.52* 1.40 ± 0.77 0.0438 1.35 ± 1.36 0.81 ± 0.32 0.83 ± 0.38 0.86 ± 0.32 NS 
Hs-CRP (mg/L) 2.26 ± 2.47 2.12 ± 1.96 1.37 ± 1.52 1.86 ± 1.87 NS 1.04 ± 1.93 0.66 ± 0.99 0.59 ± 0.83 0.94 ± 1.86 NS 
LBP (μg/ml) 22.45 ± 24.90 23.56 ± 26.42 21.63 ± 23.90 22.16 ± 22.66 NS 6.36 ± 6.67 4.83 ± 5.58 5.40 ± 5.63 5.21 ± 6.83 NS 
*
 
P < 0.05 compared to Baseline. 
 
 
Table S6. Gastrointestinal symptoms. Weekly gastrointestinal symptoms of 
the 28 participating subjects, scored in a scale from 1 (best/normal) to 5 
(worst/abnormal) during the baseline and at the end of each 4-week dietary 
treatment (BR, BR+WGB, WGB). Values are presented as mean ± SD. 
  Baseline BR BR+WGB WGB P-value 
Bowel movement 1.5 ± 0.5 1.3 ± 0.5 1.7 ± 0.6 2.0 ± 0.8¶ŦŦ < 0.01 
Stool consistency 1.5 ± 0.6 1.4 ± 0.5 1.8 ± 0.6 2.0 ± 0.8¶ŦŦ < 0.01 
General well-being 1.2 ± 0.3 1.2 ± 0.4 1.5 ± 0.6 2.2 ± 0.6¶¶¶ŦŦŦ** < 0.001 
Flatulence 1.3 ± 0.5 1.4 ± 0.5 2.2 ± 0.9¶¶¶ŦŦŦ 3.1 ± 1.0¶¶¶ŦŦŦ*** < 0.001 
Abdominal pain 1.1 ± 0.2 1.1 ± 0.3 1.4 ± 0.6 1.8 ± 0.8¶¶¶ŦŦŦ* < 0.001 
Bloating 1.2 ± 0.4 1.2 ± 0.4 1.6 ± 0.7¶Ŧ 2.2 ±0.8¶¶¶ŦŦŦ** < 0.001 
¶ Compared to baseline     






















Figure S1. Association between inflammatory and metabolic markers and 
bacterial taxa in fecal samples. A heat map shows correlation coefficients 
(Pearson) between BMI, percent body fat, IL-6, hs-CRP, LBP and glucose AUC 
with proportions of bacterial taxa in fecal samples. 
 
Figure S2. Associations between Bacteroidetes related taxa and HDL 
plasma levels at baseline. Correlations between proportions of Bacteroidetes 
(A), Bacteroidaceae (B) and Bacteroides (C) in fecal samples with HDL 
measured in plasma at baseline. Pearson’s r correlation and the P values are 
presented. 
  
Figure S3. Impact of whole grains on the fecal microbiota.  Diversity of the 
bacterial population in fecal samples assessed by Shannon’s (A) and Simpson’s 
(B) α-diversity indices.  * P < 0.05, ** P < 0.01. 
 
Figure S4. Association between diet induced shifts in glycemic response 
and the proportion of Eubacterium rectale. Correlation of the shift of the 
Eubacterium rectale abundance with the shifts observed in postprandial AUC (A), 
Insulin AUC (B), and maximum glucose levels (C).  Shift refers to differences 
between values obtained during the BR+B period and the baseline. Pearson’s r 



























































































































































































































































Difference in postprandial glucose AUC
(BR+WGB - BL) (mg/ml)
   













   
   



























Difference in postprandial insulin AUC

















Difference in postprandial glucose peak
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